Jens Samol

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Shukui Qin, Minshan Chen, Ann‐Lii Cheng et al. · The Lancet · 2023 · 488 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen et al. · Nature Medicine · 2021 · 403 citations

Medicine, Oncology, Pharmacology +6

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Hai‐Qiang Mai, Qiuyan Chen, Dongping Chen et al. · JAMA · 2023 · 233 citations · Full text

Medicine, Oncology, Pharmacology +15

Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease

Hermann Herbst, HD Foss, Jens Samol et al. · Blood · 1996 · 192 citations · Full text

Medicine, Immunology, Oncology +11

Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study

Jens Samol, Malcolm Ranson, Edwina N. Scott et al. · Investigational New Drugs · 2011 · 158 citations

Medicine, Oncology, Pharmacology +9